{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T09:31:49Z","timestamp":1789205509568,"version":"build-2803163510"},"reference-count":31,"publisher":"Georg Thieme Verlag KG","issue":"01","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Thromb Hemost"],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Abuse of anabolic\u2013androgenic steroids (AASs) is suspected to increase the risk of cardiovascular disease (CVD) and cardiovascular mortality in otherwise healthy individuals. AAS abuse may increase the incidence of CVD by altering the hemostatic balance toward a procoagulant state. Studies on the effect of AAS abuse on the fibrinolytic system, however, have either demonstrated a profibrinolytic effect or no effect of AAS abuse, but the overall effect of AAS on fibrinolysis has not been addressed so far. This cross-sectional study investigated the effect of AAS on fibrin clot lysis, fibrin structure, and the hemostatic proteins, potentially affecting these measures in current and former AAS abusers and healthy age-matched controls. The study population consisted of 37 current and 33 former AAS abusers, along with 30 healthy age-matched controls. Fibrin clot lysis, fibrin structure properties, fibrinogen, coagulation factor XIII (FXIII) plasminogen, plasmin inhibitor, plasminogen activator inhibitor-1 (PAI-1), and thrombin activatable fibrinolysis inhibitor (TAFI) were determined. Fibrin clot lysis was significantly reduced in participants abusing AAS compared with former abusers and controls (p\u2009&lt;\u20090.001). Plasma fibrinogen, plasminogen, and plasmin inhibitor were significantly increased in current abusers (p\u2009&lt;\u20090.05). No significant differences were observed with respect to measures of fibrin structure properties, PAI-1, and TAFI (p\u2009&gt;\u20090.05). In conclusion, AAS abuse depresses fibrin clot lysis. This effect is not associated with alterations in fibrin structure but is rather caused by increased plasma concentrations of fibrinogen, FXIII, and plasmin inhibitor. These findings suggest that AAS abuse may be associated with increased thrombotic disease.<\/jats:p>","DOI":"10.1055\/s-0040-1714398","type":"journal-article","created":{"date-parts":[[2020,10,5]],"date-time":"2020-10-05T23:02:55Z","timestamp":1601938975000},"page":"011-017","source":"Crossref","is-referenced-by-count":17,"title":["Anabolic\u2013Androgenic Steroid Abuse Impairs Fibrin Clot Lysis"],"prefix":"10.1055","volume":"47","author":[{"given":"Johannes Jakobsen","family":"Sidelmann","sequence":"additional","affiliation":[{"name":"Unit for Thrombosis Research, Department of Regional Health Research, University of Southern Denmark, Esbjerg, Denmark"},{"name":"Unit for Thrombosis Research, Department of Clinical Biochemistry, University Hospital of Southern Denmark, Esbjerg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f8rgen Brodersen","family":"Gram","sequence":"additional","affiliation":[{"name":"Unit for Thrombosis Research, Department of Regional Health Research, University of Southern Denmark, Esbjerg, Denmark"},{"name":"Unit for Thrombosis Research, Department of Clinical Biochemistry, University Hospital of Southern Denmark, Esbjerg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon J.","family":"Rasmussen","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Centre for Cancer and Organ Diseases, Copenhagen University Hospital, Copenhagen, Denmark"},{"name":"Department of Internal Medicine, Holb\u00e6k Hospital, Region Zealand, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Kistorp","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Centre for Cancer and Organ Diseases, Copenhagen University Hospital, Copenhagen, Denmark"},{"name":"Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2020,10,5]]},"reference":[{"issue":"04","key":"ref1","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/j.1521-0391.2013.12118.x","article-title":"The lifetime prevalence of anabolic-androgenic steroid use and dependence in Americans: current best estimates","volume":"23","author":"H G Pope Jr","year":"2014","journal-title":"Am J Addict"},{"issue":"05","key":"ref2","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.annepidem.2014.01.009","article-title":"The global epidemiology of anabolic-androgenic steroid use: a meta-analysis and meta-regression analysis","volume":"24","author":"D Sagoe","year":"2014","journal-title":"Ann Epidemiol"},{"issue":"02","key":"ref3","doi-asserted-by":"crossref","first-page":"119","DOI":"10.2165\/11598060-000000000-00000","article-title":"Anabolic steroids and cardiovascular risk","volume":"42","author":"P Angell","year":"2012","journal-title":"Sports Med"},{"issue":"21","key":"ref4","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1161\/CIRCULATIONAHA.116.026945","article-title":"Cardiovascular toxicity of illicit anabolic-androgenic steroid use","volume":"135","author":"A L Baggish","year":"2017","journal-title":"Circulation"},{"issue":"01","key":"ref5","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1161\/CIRCULATIONAHA.116.022535","article-title":"Cardiovascular effects of performance-enhancing drugs","volume":"135","author":"A La Gerche","year":"2017","journal-title":"Circulation"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ahj.2018.06.010","article-title":"Cardiac systolic dysfunction in past illicit users of anabolic androgenic steroids","volume":"203","author":"J J Rasmussen","year":"2018","journal-title":"Am Heart J"},{"issue":"08","key":"ref7","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1055\/s-0031-1297371","article-title":"Doping and thrombosis in sports","volume":"37","author":"G Lippi","year":"2011","journal-title":"Semin Thromb Hemost"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.drugalcdep.2015.04.013","article-title":"Anabolic steroids and cardiovascular risk: a national population-based cohort study","volume":"152","author":"I Thiblin","year":"2015","journal-title":"Drug Alcohol Depend"},{"issue":"04","key":"ref9","first-page":"647","article-title":"Procoagulant state in current and former anabolic androgenic steroid abusers","volume":"118","author":"S Chang","year":"2018","journal-title":"Thromb Haemost"},{"issue":"08","key":"ref10","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1055\/s-0038-1670639","article-title":"Anabolic androgenic steroid abuse: the effects on thrombosis risk, coagulation, and fibrinolysis","volume":"44","author":"S Chang","year":"2018","journal-title":"Semin Thromb Hemost"},{"issue":"06","key":"ref11","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1080\/07853890600852898","article-title":"Thrombin activatable fibrinolysis inhibitor (TAFI)--how does thrombin regulate fibrinolysis?","volume":"38","author":"B N Bouma","year":"2006","journal-title":"Ann Med"},{"issue":"12","key":"ref12","doi-asserted-by":"crossref","first-page":"e88","DOI":"10.1161\/ATVBAHA.111.230631","article-title":"Fibrin clot structure and function: a role in the pathophysiology of arterial and venous thromboembolic diseases","volume":"31","author":"A Undas","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"02","key":"ref13","first-page":"178","article-title":"Decreased plasma fibrinolytic potential as a risk for venous and arterial thrombosis","volume":"43","author":"T Lisman","year":"2017","journal-title":"Semin Thromb Hemost"},{"issue":"08","key":"ref14","doi-asserted-by":"crossref","first-page":"e0161208","DOI":"10.1371\/journal.pone.0161208","article-title":"Former abusers of anabolic androgenic steroids exhibit decreased testosterone levels and hypogonadal symptoms years after cessation: a case-control study","volume":"11","author":"J J Rasmussen","year":"2016","journal-title":"PLoS One"},{"issue":"03","key":"ref15","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/cen.13372","article-title":"Insulin sensitivity in relation to fat distribution and plasma adipocytokines among abusers of anabolic androgenic steroids","volume":"87","author":"J J Rasmussen","year":"2017","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"02","key":"ref16","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/HJH.0000000000001546","article-title":"Increased blood pressure and aortic stiffness among abusers of anabolic androgenic steroids: potential effect of suppressed natriuretic peptides in plasma?","volume":"36","author":"J J Rasmussen","year":"2018","journal-title":"J Hypertens"},{"issue":"06","key":"ref17","doi-asserted-by":"crossref","first-page":"E1172","DOI":"10.1152\/ajpendo.2001.281.6.E1172","article-title":"Testosterone dose-response relationships in healthy young men","volume":"281","author":"S Bhasin","year":"2001","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"03","key":"ref18","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.thromres.2014.06.031","article-title":"Lysability of fibrin clots is a potential new determinant of stroke risk in atrial fibrillation","volume":"134","author":"J Skov","year":"2014","journal-title":"Thromb Res"},{"issue":"02","key":"ref19","first-page":"339","article-title":"Fibrin clot structure in patients with end-stage renal disease","volume":"98","author":"J A Sj\u00f8land","year":"2007","journal-title":"Thromb Haemost"},{"issue":"06","key":"ref20","first-page":"985","article-title":"The effect of dextran 70 on the structure of plasma-derived fibrin gels","volume":"96","author":"M E Carr","year":"1980","journal-title":"J Lab Clin Med"},{"issue":"01","key":"ref21","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1021\/ma60061a009","article-title":"Size and density of fibrin fibers from turbidity","volume":"11","author":"M E Carr Jr","year":"1978","journal-title":"Macromolecules"},{"key":"ref22","first-page":"83","volume-title":"Contact Activation of the Fibrinolytic System in Human Blood [PhD dissertation]","author":"J Sidelmann","year":"1997"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1209676","DOI":"10.1155\/2017\/1209676","article-title":"Inhibition of fibrinolysis by coagulation factor XIII","volume":"2017","author":"D C Rijken","year":"2017","journal-title":"BioMed Res Int"},{"issue":"11","key":"ref24","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1161\/01.ATV.0000241589.52950.4c","article-title":"Altered fibrin architecture is associated with hypofibrinolysis and premature coronary atherothrombosis","volume":"26","author":"J P Collet","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"04","key":"ref25","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/ajh.2830480402","article-title":"Idiopathic osteonecrosis, hypofibrinolysis, high plasminogen activator inhibitor, high lipoprotein(a), and therapy with Stanozolol","volume":"48","author":"C J Glueck","year":"1995","journal-title":"Am J Hematol"},{"issue":"02","key":"ref26","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1055\/s-0038-1661049","article-title":"Stanozolol-induced changes in fibrinolysis and coagulation in healthy adults","volume":"51","author":"C Kluft","year":"1984","journal-title":"Thromb Haemost"},{"issue":"05","key":"ref27","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0049-3848(97)00163-1","article-title":"Efficacy of danazol in a patient with congenital protein-S deficiency: paradoxical evidence for decreased platelet activation with increased thrombin generation","volume":"87","author":"M R Ledford","year":"1997","journal-title":"Thromb Res"},{"issue":"01","key":"ref28","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0049-3848(82)90030-5","article-title":"The effect of intramuscular stanozolol on fibrinolysis and blood lipids","volume":"28","author":"M Small","year":"1982","journal-title":"Thromb Res"},{"issue":"06","key":"ref29","first-page":"698","article-title":"Some clotting factors in plasma during danazol therapy: free and total protein S, but not C4b-binding protein, are elevated by danazol therapy","volume":"119","author":"H Thorisdottir","year":"1992","journal-title":"J Lab Clin Med"},{"issue":"08","key":"ref30","doi-asserted-by":"crossref","first-page":"513","DOI":"10.2165\/00007256-200434080-00003","article-title":"Effects of androgenic-anabolic steroids in athletes","volume":"34","author":"F Hartgens","year":"2004","journal-title":"Sports Med"},{"issue":"02","key":"ref31","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/ajh.20532","article-title":"Effects of oxandrolone, an anabolic steroid, on hemostasis","volume":"81","author":"N N Kahn","year":"2006","journal-title":"Am J Hematol"}],"container-title":["Seminars in Thrombosis and Hemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0040-1714398.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T23:51:05Z","timestamp":1612223465000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0040-1714398"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,5]]},"references-count":31,"journal-issue":{"issue":"01","published-online":{"date-parts":[[2021,2,1]]},"published-print":{"date-parts":[[2021,2]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0040-1714398","relation":{},"ISSN":["0094-6176","1098-9064"],"issn-type":[{"value":"0094-6176","type":"print"},{"value":"1098-9064","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,5]]}}}